Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931163 · ClinicalTrials.gov registry record · Phase 2
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
A Phase 2 study, sponsored by Jenny C. Chang, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01931163: Completed Phase 2 study, sponsored by Jenny C. Chang, MD.
NCT01931163 is a Phase 2 study that has completed, run by Jenny C. Chang, MD. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01931163, a Phase 2 study, has completed, sponsored by Jenny C. Chang, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subjects with triple negative breast cancer who have residual disease after chemotherapy.
Primary Outcome
Evaluate tumor response using RECIST criteria after 12 weeks of treatment at definitive surgery. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
What the finished NCT01931163 record still lists
NCT01931163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT01931163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01931163 about?
NCT01931163 is a clinical study titled "NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer". RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subject...
What is the current status of trial NCT01931163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01931163?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT01931163?
This trial is sponsored by Jenny C. Chang, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01931163's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia